At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 206 enrolled
Drug / intervention
KRX-0502drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia
In Brief
A Phase 4 clinical trial evaluating KRX-0502 for Chronic Kidney Diseases and Iron Deficiency Anemia. Completed, enrolled 206 participants across 28 sites.
Detailed Summary
The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney disease (CKD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases, Iron Deficiency Anemia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionAug 2019
Study CompletionSep 2019
TodayJul 2026
First PostedAug 1, 2017
Enrollment StartAug 15, 2017
Primary CompletionAug 30, 2019
Study CompletionSep 27, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.9 years ago
Interventions
KRX-0502drug
Oral ferric citrate with meals